As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

Symptoms of NAION can include blurred vision, peripheral vision loss, dark spots in vision, and changes in color perception. Though the exact mechanism is not fully understood, researchers hypothesize ...

Dr. Sue Mitchell is an experienced gastroenterologist with a background in functional medicine, internal medicine and ...

Cleveland Clinic experts reveals what's behind "Ozempic face," and list the semaglutide-associated symptoms that can call for ...

Eden is providing access to a new way for individuals to explore GLP-1 therapy: a compounded semaglutide gummy, available ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with ...